No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NSPR InspireMD
- 2.660
- -0.027-0.99%
Close Jun 10 16:00 ET
- 2.622
- -0.038-1.43%
Post 19:21 ET
66.38MMarket Cap-5319P/E (TTM)
2.700High2.650Low17.17KVolume2.700Open2.686Pre Close45.61KTurnover0.18%Turnover RatioLossP/E (Static)24.96MShares3.85052wk High1.89P/B25.06MFloat Cap1.81052wk Low--Dividend TTM9.42MShs Float75862432.808Historical High--Div YieldTTM1.86%Amplitude0.806Historical Low2.656Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | InspireMD: Files Prospectus Supplement to Offer, Sell Common Stock of up to $17 Mln From Time to Time Under Equity Distribution Deal With Piper Sandler
InspireMD's CGuard Stent Shows Promise in C-GUARDIANS Trial
Express News | InspireMD Presents One-Year Follow-Up Results From C-GUARDIANS US IDE Trial Of CGuard At LINC 2024 On May 28 At 8:53 A.m. EDT
Express News | InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved
Express News | InspireMD Inc -Study Results to Support a Premarket Approval (Pma) Application to FDA in H2 2024
Express News | InspireMD Announces Presentation of Positive One-Year Follow-up Results From the C-Guardians U.S. Investigational Device Exemption (Ide) Clinical Trial of Cguard at Linc 2024
Comments
$InspireMD(NSPR.US$ InspireMD Inc -U.S. Commercial Launch of Cguard™ Prime Carotid Stent System Anticipated in H1 2025, IF Approved
$InspireMD(NSPR.US$ INSPIREMD INC -STUDY RESULTS TO SUPPORT A PREMARKET APPROVAL (PMA) APPLICATION TO FDA IN H2 2024
Reuters05/28/2024 08:53
Reuters05/28/2024 08:53
$InspireMD(NSPR.US$ InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 60.38 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $1.511 billion which beat the analyst consensus estimate of $1.384 million by 109.08K percent. This is a 121.85K percent increase over sales of $1.239 million the same period...
$InspireMD(NSPR.US$ InspireMD Announces Abstract Of One-year Follow-up Results From C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial Accepted For Presentation At LINC 2024
Benzinga· 1 min ago
Benzinga· 1 min ago
$InspireMD(NSPR.US$ InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework
3 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE![]()
3 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg